TRK-IN-32

• Description:

  TRK-IN-32 is a potent TRK inhibitor. TRK-IN-32 potently inhibits TRKWT, TRKG595R and TRKG667C with IC50 values of 0.08 nM, 2.14 nM and 0.68 nM, respectively. TRK-IN-32 also demonstrates antiproliferative activity against a panel of Ba/F3 cell lines transformed with wild type, xDFG, solvent-front as well as gatekeeper mutant TRK fusion proteins. TRK-IN-32 induces apoptosis of Ba/F3-TRKAWT and Ba/F3-TRKAG667C cells.TRK-IN-32 can be used for the study of various cancers (such as thyroid cancer, secretory breast carcinoma) [1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Trk Receptor

• Related Pathways:

  Apoptosis; Neuronal Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  C[C@@H] (C1=CC=C (C=N1) F) NC2=NN3C (C4=NNC (C5CC5) =C4) =CN=C3C=C2

• Molecular Formula:

  C19H18FN7

• Molecular Weight:

  363.39

• References & Citations:

  [1]Xu Y, et al. Discovery of imidazo[1,2-b]pyridazine derivatives as potent TRK inhibitors for overcoming multiple resistant mutants. Bioorg Chem. 2025 Aug;163:108737.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  3044124-79-7